Advertisement

Death Receptors in Multiple Myeloma and Therapeutic Opportunities

  • Faustino Mollinedo
Part of the Contemporary Hematology book series (CH)

Introduction

Multiple myeloma (MM) is a malignancy of terminally differentiated B-lymphocytes, also known as plasma cells, that accounts for about 10% of all hematologic cancers,1 ranking as the second most common blood cancer, after non-Hodgkin lymphoma.2MM is characterized by a clonal expansion and accumulation of malignant plasma cells within the bone marrow (BM), serum and/or urine monoclonal immunoglobulin, and osteolytic lesions. Because of the infiltration and growth of myeloma cells in the local BM microenvironment, MM patients commonly develop osteolytic bone disease, which predominantly affects the skull, ribs, vertebrae, pelvis, and proximal long bones. The interaction of myeloma cells with cells of the BM microenvironment leads to disruption of normal hematopoiesis, neutropenia, anemia, bone destruction, and hiper-calcemia. Thus, most patients with MM will have pathological fractures or develop some form of osteolytic bone disease during the course of their disease,...

Keywords

Multiple Myeloma U266 Cell Lipid Raft Death Receptor Myeloma Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Rajkumar SV, Gertz MA, Kyle RA, Greipp PR. Current therapy for multiple myeloma. Mayo Clin Proc2002; 77:813–22.Google Scholar
  2. 2.
    Hussein MA, Juturi JV, Lieberman I. Multiple myeloma: Present and future. Curr Opin Oncol 2002; 14:31–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Mundy GR. Myeloma bone disease. Eur J Cancer 1998; 34:246–51.PubMedCrossRefGoogle Scholar
  4. 4.
    Barille-Nion S, Bataille R. New insights in myeloma-induced osteolysis. Leuk Lymphoma 2003; 44:1463–7.CrossRefGoogle Scholar
  5. 5.
    Epstein J, Yaccoby S. Consequences of interactions between the bone marrow stroma and myeloma. Hematol J 2003; 4:310–4.PubMedCrossRefGoogle Scholar
  6. 6.
    Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349:2483–94.PubMedCrossRefGoogle Scholar
  7. 7.
    Kuehl WM, Bergsagel PL. Multiple myeloma: Evolving genetic events and host interactions. Nat Rev Cancer 2002; 2:175–87.PubMedCrossRefGoogle Scholar
  8. 8.
    Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 2000; 256:58–66.PubMedCrossRefGoogle Scholar
  9. 9.
    Wajant H. The Fas signaling pathway: More than a paradigm. Science 2002; 296:1635–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene 2004; 23:2950–66.PubMedCrossRefGoogle Scholar
  11. 11.
    Marsters SA, Sheridan JP, Donahue CJ, et al. Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B. Curr Biol 1996; 6:1669–76.PubMedCrossRefGoogle Scholar
  12. 12.
    PanG, Bauer JH, Haridas V, et al. Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett 1998; 431:351–6.PubMedCrossRefGoogle Scholar
  13. 13.
    El-DeiryWS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ 2001; 8:1066–75.CrossRefGoogle Scholar
  14. 14.
    Mollinedo F, Gajate C, Martin-Santamaria S, Gago F. ET-18-OCH3 (edelfosine): A selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor. Curr Med Chem 2004; 11:3163–84.PubMedGoogle Scholar
  15. 15.
    Hainaut P, Hollstein M. p53 and human cancer: The first ten thousand mutations. Adv Cancer Res 2000; 77:81–137.PubMedCrossRefGoogle Scholar
  16. 16.
    Mazars GR, Portier M, Zhang XG, et al. Mutations of the p53 gene in human myeloma cell lines. Oncogene1992; 7:1015–8.PubMedGoogle Scholar
  17. 17.
    Neri A, Baldini L, Trecca D, Cro L, Polli E, Maiolo AT. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 1993 ; 81:128–35.PubMedGoogle Scholar
  18. 18.
    Avet-Loiseau H, Li JY, Godon C, et al. P53 deletion is not a frequent event in multiple myeloma. Br J Haematol 1999; 106:717–9.CrossRefGoogle Scholar
  19. 19.
    Chang H, Qi C, Yi QL, Reece D, Stewart AK. p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood 2005; 105:358–60.PubMedCrossRefGoogle Scholar
  20. 20.
    Stuhmer T, ChatterjeeM, Hildebrandt M, et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 2005; 106:3609–17.PubMedCrossRefGoogle Scholar
  21. 21.
    Liu Q, El-Deiry WS, Gazitt Y. Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines. Exp Hematol 2001; 29:962–70.PubMedCrossRefGoogle Scholar
  22. 22.
    Itoh N, Yonehara S, Ishii A, et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991; 66:233–43.PubMedCrossRefGoogle Scholar
  23. 23.
    Itoh N, Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 1993; 268:10932–7.PubMedGoogle Scholar
  24. 24.
    Nagata S. Apoptosis by death factor. Cell 1997; 88:355–65.PubMedCrossRefGoogle Scholar
  25. 25.
    Huang B, Eberstadt M, Olejniczak ET, Meadows RP, Fesik SW. NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain. Nature 1996; 384:638–41.PubMedCrossRefGoogle Scholar
  26. 26.
    Siegel RM, Chan FK, Chun HJ, Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 2000; 1:469–74.PubMedCrossRefGoogle Scholar
  27. 27.
    Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000; 288:2351–4.PubMedCrossRefGoogle Scholar
  28. 28.
    Papoff G, Hausler P, Eramo A, et al. Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor. J Biol Chem 1999; 274:38241–50.PubMedCrossRefGoogle Scholar
  29. 29.
    Siegel RM, Frederiksen JK, Zacharias DA, et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000; 288:2354–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81:505–12.PubMedCrossRefGoogle Scholar
  31. 31.
    Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996; 85:803–15.PubMedCrossRefGoogle Scholar
  32. 32.
    Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998; 281:1305–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Kischkel FC, Hellbardt S, Behrmann I, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. Embo J 1995; 14:5579–88.PubMedGoogle Scholar
  34. 34.
    Parlato S, Giammarioli AM, Logozzi M, et al. CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: A novel regulatory mechanism of the CD95 apoptotic pathway. Embo J 2000; 19:5123–34.PubMedCrossRefGoogle Scholar
  35. 35.
    Gajate C, Mollinedo F. Cytoskeleton-mediated Death Receptor and Ligand Concentration in Lipid Rafts Forms Apoptosis-promoting Clusters in Cancer Chemotherapy. J Biol Chem 2005; 280:11641–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Gajate C, Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 2007; 109:711–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Gajate C, Fonteriz RI, Cabaner C, et al. Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis. Int J Cancer 2000; 85:674–82.PubMedCrossRefGoogle Scholar
  38. 38.
    Gajate C, Del Canto-Janez E, Acuna AU, et al. Intracellular Triggering of Fas Aggregation and Recruitment of Apoptotic Molecules into Fas-enriched Rafts in Selective Tumor Cell Apoptosis. J Exp Med 2004; 200:353–65.PubMedCrossRefGoogle Scholar
  39. 39.
    Mollinedo F, Gajate C. FasL-independent activation of Fas. In: Wajant H, ed. Fas Signaling. Georgetown, TX : Landes Bioscience and Springer Science, 2006: Chapter 2, pp. 13–27.CrossRefGoogle Scholar
  40. 40.
    Mollinedo F, Gajate C. Fas/CD95 death receptor and lipid rafts: New targets for apoptosis-directed cancer therapy. Drug Resist Updat 2006; 9:51–73.PubMedCrossRefGoogle Scholar
  41. 41.
    Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388:190–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Kataoka T. The caspase-8 modulator c-FLIP. Crit Rev Immunol 2005; 25:31–58.PubMedCrossRefGoogle Scholar
  43. 43.
    Chang DW, Xing Z, Pan Y, et al. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. Embo J 2002; 21:3704–14.PubMedCrossRefGoogle Scholar
  44. 44.
    Micheau O, Thome M, Schneider P, et al. The long form of FLIP is an activator of cas-pase-8 at the Fas death-inducing signaling complex. J Biol Chem 2002; 277:45162–71.PubMedCrossRefGoogle Scholar
  45. 45.
    Rasper DM, Vaillancourt JP, Hadano S, et al. Cell death attenuation by ‘Usurpin’, a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. Cell Death Differ 1998; 5:271–88.PubMedCrossRefGoogle Scholar
  46. 46.
    Yeh WC, Pompa JL, McCurrach ME, et al. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science 1998; 279:1954–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Yeh WC, Itie A, Elia AJ, et al. Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity 2000; 12:633–42.PubMedCrossRefGoogle Scholar
  48. 48.
    Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: Decisions between life and death. Int J Biochem Cell Biol 2007.Google Scholar
  49. 49.
    Kelley RF, Totpal K, Lindstrom SH, et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling J Biol Chem 2005; 280:2205–12.PubMedCrossRefGoogle Scholar
  50. 50.
    de Vries EG, Timmer T, Mulder NH, et al. Modulation of death receptor pathways in oncology. Drugs Today (Barc) 2003; 39 (Suppl C):95–109.PubMedGoogle Scholar
  51. 51.
    Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364:806–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Faubion WA, Gores GJ. Death receptors in liver biology and pathobiology. Hepatology 1999; 29:1–4.PubMedCrossRefGoogle Scholar
  53. 53.
    Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673–82.PubMedCrossRefGoogle Scholar
  54. 54.
    Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271:12687–90.PubMedCrossRefGoogle Scholar
  55. 55.
    Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5:157–63.PubMedCrossRefGoogle Scholar
  56. 56.
    Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104:155–62.PubMedCrossRefGoogle Scholar
  57. 57.
    Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6:564–7.PubMedCrossRefGoogle Scholar
  58. 58.
    Leverkus M, Neumann M, MenglingT, et al. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 2000; 60:553–9.PubMedGoogle Scholar
  59. 59.
    Nesterov A, Ivashchenko Y, Kraft AS. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in normal prostate epithelial cells. Oncogene 2002; 21:1135–40.PubMedCrossRefGoogle Scholar
  60. 60.
    Nitsch R, Bechmann I, Deisz RA, et al. Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet 2000; 356:827–8.PubMedCrossRefGoogle Scholar
  61. 61.
    Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. Targeting death-inducing receptors in cancer therapy. Oncogene 2007; 26:3745–57.PubMedCrossRefGoogle Scholar
  62. 62.
    Kelley SK, Harris LA, Xie D, et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: Characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001; 299:31–8.PubMedGoogle Scholar
  63. 63.
    Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005; 5:876–85.PubMedCrossRefGoogle Scholar
  64. 64.
    Clodi K, Wimmer D, Li Y, et al. Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells. Br J Haematol 2000; 111:580–6.PubMedCrossRefGoogle Scholar
  65. 65.
    Lincz LF, Yeh TX, Spencer A. TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia 2001; 15:1650–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273:14363–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Truneh A, Sharma S, Silverman C, et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 2000; 275:23319–25.PubMedCrossRefGoogle Scholar
  68. 68.
    Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309–19.PubMedCrossRefGoogle Scholar
  69. 69.
    Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165–76.PubMedCrossRefGoogle Scholar
  70. 70.
    Nakagawa N, Kinosaki M, Yamaguchi K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998; 253:395–400.PubMedCrossRefGoogle Scholar
  71. 71.
    Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397:315–23.PubMedCrossRefGoogle Scholar
  72. 72.
    Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999; 145:527–38.PubMedCrossRefGoogle Scholar
  73. 73.
    De Leenheer E, Mueller GS, Vanderkerken K, Croucher PI. Evidence of a role for RANKL in the development of myeloma bone disease. Curr Opin Pharmacol 2004; 4:340–6.PubMedCrossRefGoogle Scholar
  74. 74.
    Bucay N, Sarosi I, Dunstan CR, et al. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12:1260–8.PubMedCrossRefGoogle Scholar
  75. 75.
    Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclas-togenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998; 247:610–5.PubMedCrossRefGoogle Scholar
  76. 76.
    Gajate C, Mollinedo F. The antitumor ether lipid ET-18-OCH3 induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood 2001; 98:3860–3.PubMedCrossRefGoogle Scholar
  77. 77.
    Varma R, Mayor S. GPI-anchored proteins are organized in submicron domains at the cell surface. Nature1998; 394:798–801.PubMedCrossRefGoogle Scholar
  78. 78.
    Hueber AO, Bernard AM, Herincs Z, Couzinet A, He HT. An essential role for membrane rafts in the initiation of Fas/CD95-triggered cell death in mouse thymo-cytes. EMBO Rep 2002; 3:190–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Scheel-Toellner D, Wang K, Singh R, et al. The death-inducing signalling complex is recruited to lipid rafts in Fas-induced apoptosis. Biochem Biophys Res Commun 2002; 297:876–9.CrossRefGoogle Scholar
  80. 80.
    Delmas D, Rebe C, Lacour S, et al. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J Biol Chem 2003; 278:41482–90.PubMedCrossRefGoogle Scholar
  81. 81.
    Chakrabandhu K, Herincs Z, Huault S, et al. Palmitoylation is required for efficient Fas cell death signaling. Embo J 2007; 26:209–20.PubMedCrossRefGoogle Scholar
  82. 82.
    Krammer PH. CD95's deadly mission in the immune system. Nature 2000; 407:789–95.PubMedCrossRefGoogle Scholar
  83. 83.
    Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WS. Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997; 90:4266–70.PubMedGoogle Scholar
  84. 84.
    ShimaY, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K, Kishimoto T. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 1995; 85:757–64.PubMedGoogle Scholar
  85. 85.
    Westendorf JJ, Lammert JM, Jelinek DF. Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. Blood 1995; 85:3566–76.PubMedGoogle Scholar
  86. 86.
    Hata H, Matsuzaki H, Takeya M, et al. Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders. Blood 1995; 86:1939–45.PubMedGoogle Scholar
  87. 87.
    Kim DK, Cho ES, Yoo JH, Um HD. FLIP is constitutively hyperexpressed in Fas-resistant U266 myeloma cells, but is not induced by IL-6 in Fas-sensitive RPM18226 cells. Mol Cells 2000; 10:552–6.PubMedCrossRefGoogle Scholar
  88. 88.
    Munshi NC, Hideshima T, Carrasco D, et al. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 2004; 103:1799–806.PubMedCrossRefGoogle Scholar
  89. 89.
    Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10:105–15.CrossRefGoogle Scholar
  90. 90.
    Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332:83–5.PubMedCrossRefGoogle Scholar
  91. 91.
    Zhang XG, Klein B, Bataille R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 1989; 74:11–3.PubMedGoogle Scholar
  92. 92.
    Hardin J, MacLeod S, Grigorieva I, et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994; 84:3063–70.PubMedGoogle Scholar
  93. 93.
    Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. Interleukin-6 inhibits apop-tosis of malignant plasma cells. Cell Immunol 1995; 162:248–55.PubMedCrossRefGoogle Scholar
  94. 94.
    Barut BA, Zon LI, Cochran MK, et al. Role of interleukin 6 in the growth of myeloma-derived cell lines. Leuk Res1992; 16:951–9.PubMedCrossRefGoogle Scholar
  95. 95.
    Chauhan D, Kharbanda S, Ogata A, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997; 89:227–34.PubMedGoogle Scholar
  96. 96.
    Xu FH, Sharma S, Gardner A, et al. Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: Support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway. Blood 1998; 92:241–51.PubMedGoogle Scholar
  97. 97.
    Blade J, Lopez-Guillermo A, Tassies D, Montserrat E, Rozman C. Development of aggressive plasma cell leukaemia under interferon-alpha therapy. Br J Haematol 1991; 79:523–5.PubMedCrossRefGoogle Scholar
  98. 98.
    Shustik C. Interferon in the Treatment of Multiple Myeloma. Cancer Control 1998; 5:226–34.PubMedGoogle Scholar
  99. 99.
    Tu KL, Bowyer J, Schofield K, Harding S. Severe interferon associated retinopa-thy. Br J Ophthalmol 2003; 87:247–8.PubMedCrossRefGoogle Scholar
  100. 100.
    Schaar CG, Kluin-Nelemans HC, Te Marvelde C, et al. Interferon-alpha as maintenance therapy in patients with multiple myeloma. Ann Oncol2005; 16:634–9.PubMedCrossRefGoogle Scholar
  101. 101.
    Spets H, Georgii-Hemming P, Siljason J, Nilsson K, Jernberg-Wiklund H. Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-gamma and inter-feron- in interleukin-6 (IL-6)-dependent and IL-6-independent multiple myeloma cell lines. Blood 1998; 92:2914–23.PubMedGoogle Scholar
  102. 102.
    Dimberg LY, DimbergAI, Ivarsson K, et al. Ectopic and IFN-induced expression of Fas overcomes resistance to Fas-mediated apoptosis in multiple myeloma cells. Blood 2005; 106:1346–54.PubMedCrossRefGoogle Scholar
  103. 103.
    Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene 2000; 19:2474–88.PubMedCrossRefGoogle Scholar
  104. 104.
    Ivanov VN, Bhoumik A, Krasilnikov M, et al. Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell 2001; 7:517–28.PubMedCrossRefGoogle Scholar
  105. 105.
    Alas S, Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res 2003; 9:316–26.PubMedGoogle Scholar
  106. 106.
    Xu X, Fu XY, Plate J, Chong AS. IFN-gamma induces cell growth inhibition by Fas-mediated apoptosis: Requirement of STAT1 protein for up-regulation of Fas and FasL expression. Cancer Res 1998; 58:2832–7.PubMedGoogle Scholar
  107. 107.
    Shen Y, Devgan G, Darnell JE, Jr., Bromberg JF. Constitutively activated Stat3 protects fibroblasts from serum withdrawal and UV-induced apoptosis and antagonizes the proapoptotic effects of activated Stat1. Proc Natl Acad Sci USA 2001; 98:1543–8.PubMedCrossRefGoogle Scholar
  108. 108.
    Hong F, Jaruga B, Kim WH, et al. Opposing roles of STAT1 and STAT3 in T cell mediated hepatitis: Regulation by SOCS. J Clin Invest 2002; 110:1503–13.PubMedGoogle Scholar
  109. 109.
    Stephanou A, Brar BK, Knight RA, Latchman DS. Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ 2000; 7:329–30.PubMedCrossRefGoogle Scholar
  110. 110.
    Shain KH, Landowski TH, Buyuksal I, Cantor AB, Dalton WS. Clonal variability in CD95 expression is the major determinant in Fas-medicated, but not chemotherapy-medicated apoptosis in the RPMI 8226 multiple myeloma cell line. Leukemia 2000; 14:830–40.PubMedCrossRefGoogle Scholar
  111. 111.
    Gajate C, Mollinedo F. Biological activities, mechanisms of action and bio-medical prospect of the antitumor ether phospholipid ET-18-OCH3 (edelfosine), a proapoptotic agent in tumor cells. Curr Drug Metab 2002; 3:491–525.PubMedCrossRefGoogle Scholar
  112. 112.
    Mollinedo F. Antitumor ether lipids: Proapoptotic agents with multiple therapeutic indications. Expert Opin Ther Patents 2007; 17:385–405.CrossRefGoogle Scholar
  113. 113.
    Yagita H, Takeda K, Hayakawa Y, Smyth MJ, OkumuraK. TRAIL and its receptors as targets for cancer therapy. Cancer Sci 2004; 95:777–83.PubMedCrossRefGoogle Scholar
  114. 114.
    Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 1999; 13:1817–24.PubMedCrossRefGoogle Scholar
  115. 115.
    Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: Therapeutic applications. Blood 2001; 98:795–804.PubMedCrossRefGoogle Scholar
  116. 116.
    Glasser L, Dalton WS, Fiederlein RL, Cook P, Powis G, Vogler WR. Response of human multiple myeloma-derived cell lines to alkyl-lysophospholipid. Exp Hematol 1996; 24:253–7.PubMedGoogle Scholar
  117. 117.
    Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkyl-phospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107:4053–62.PubMedCrossRefGoogle Scholar
  118. 118.
    Berdel WE, Bausert WR, Fink U, Rastetter J, Munder PG. Anti-tumor action of alkyl-lysophospholipids (review). Anticancer Res 1981; 1:345–52.PubMedGoogle Scholar
  119. 119.
    Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-kappaB and upregula-tion of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: Therapeutic implications. Oncogene 2002; 21:5673–83.PubMedCrossRefGoogle Scholar
  120. 120.
    Chen Q, Ray S, Hussein MA, Srkalovic G, Almasan A. Role of Apo2L/TRAIL and Bcl-2-family proteins in apoptosis of multiple myeloma. Leuk Lymphoma 2003; 44:1209–14.PubMedCrossRefGoogle Scholar
  121. 121.
    Gomez-Benito M, Martinez-Lorenzo MJ, Anel A, Marzo I, Naval J. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Exp Cell Res 2007; 313:2378–88.CrossRefGoogle Scholar
  122. 122.
    Chen Q, Gong B, Mahmoud-Ahmed AS, et al. Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. Blood 2001; 98:2183–92.PubMedCrossRefGoogle Scholar
  123. 123.
    Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 2002; 99:2162–71.PubMedCrossRefGoogle Scholar
  124. 124.
    Spencer A, Yeh SL, Koutrevelis K, Baulch-Brown C. TRAIL-induced apoptosis of authentic myeloma cells does not correlate with the procaspase-8/cFLIP ratio. Blood 2002; 100:3049; author reply 3050–1.Google Scholar
  125. 125.
    Crowder C, Dahle O, Davis RE, Gabrielsen OS, Rudikoff S. PML mediates IFN-alpha-induced apoptosis in myeloma by regulating TRAIL induction. Blood 2005; 105:1280–7.PubMedCrossRefGoogle Scholar
  126. 126.
    MacFarlane M, Inoue S, Kohlhaas SL, et al. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ2005; 12:773–82.PubMedCrossRefGoogle Scholar
  127. 127.
    Menoret E, Gomez-Bougie P, Geffroy-Luseau A, et al. Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood 2006 ; 108 : 1346–52.PubMedCrossRefGoogle Scholar
  128. 128.
    Roodman GD. Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 1997; 80:1557–63.PubMedCrossRefGoogle Scholar
  129. 129.
    Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351:1860–73.PubMedCrossRefGoogle Scholar
  130. 130.
    Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423:337–42.PubMedCrossRefGoogle Scholar
  131. 131.
    Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: Focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol 2004; 32:685–91.PubMedCrossRefGoogle Scholar
  132. 132.
    Hjorth-Hansen H, Seifert MF, Borset M, et al. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res 1999; 14:256–63.CrossRefGoogle Scholar
  133. 133.
    Giuliani N, Colla S, Sala R, et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: A potential role in multiple myeloma bone disease. Blood 2002; 100:4615–21.PubMedCrossRefGoogle Scholar
  134. 134.
    Colucci S, Brunetti G, Rizzi R, et al. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: The role of the OPG/TRAIL interaction. Blood 2004; 104:3722–30.PubMedCrossRefGoogle Scholar
  135. 135.
    O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Cancer as a site of immune privilege. Immunol Today 1999; 20:46–52.PubMedCrossRefGoogle Scholar
  136. 136.
    Villunger A, Egle A, Marschitz I, et al. Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: A potential mechanism of tumor-induced suppression of immune surveillance. Blood 1997; 90:12–20.PubMedGoogle Scholar
  137. 137.
    Silvestris F, Cafforio P, Tucci M, Dammacco F. Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: A major pathoge-netic mechanism of anemia in multiple myeloma. Blood 2002; 99:1305–13.PubMedCrossRefGoogle Scholar
  138. 138.
    Tinhofer I, Biedermann R, Krismer M, Crazzolara R, Greil R. A role of TRAIL in killing osteoblasts by myeloma cells. Faseb J 2006; 20:759–61.PubMedGoogle Scholar
  139. 139.
    Silvestris F, Tucci M, Cafforio P, Dammacco F. Fas-L up-regulation by highly malignant myeloma plasma cells: Role in the pathogenesis of anemia and disease progression. Blood 2001; 97:1155–64.PubMedCrossRefGoogle Scholar
  140. 140.
    Menu E, Kooijman R, Van Valckenborgh E, et al. Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma c ells: Study in the 5T33MM model. Br J Cancer 2004; 90:1076–83.PubMedCrossRefGoogle Scholar
  141. 141.
    Silvestris F, Cafforio P, Tucci M, Grinello D, Dammacco F. Upregulation of oste-oblast apoptosis by malignant plasma cells: A role in myeloma bone disease. Br J Haematol 2003; 122:39–52.PubMedCrossRefGoogle Scholar
  142. 142.
    Silvestris F, Cafforio P, Calvani N, Dammacco F. Impaired osteoblastogenesis in myeloma bone disease: Role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol2004; 126:475–86.PubMedCrossRefGoogle Scholar
  143. 143.
    Leithauser F, Dhein J, Mechtersheimer G, et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest1993; 69:415–29.PubMedGoogle Scholar
  144. 144.
    Atkins GJ, Bouralexis S, Evdokiou A, et al. Human osteoblasts are resistant to Apo2L/TRAIL-mediated apoptosis. Bone 2002; 31:448–56.PubMedCrossRefGoogle Scholar
  145. 145.
    Ursini-Siegel J, Zhang W, Altmeyer A, et al. TRAIL/Apo-2 ligand induces primary plasma cell apoptosis. J Immunol 2002; 169:5505–13.Google Scholar
  146. 146.
    Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277:16639–47.PubMedCrossRefGoogle Scholar
  147. 147.
    Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003; 63:912–6.PubMedGoogle Scholar
  148. 148.
    Sezer O, Heider U, Jakob C, Eucker J, Possinger K. Human bone marrow myeloma cells express RANKL. J Clin Oncol 2002; 20:353–4.PubMedGoogle Scholar
  149. 149.
    Sezer O, Heider U, Jakob C, et al. Immunocytochemistry reveals RANKL expression of myeloma cells. Blood 2002; 99:4646–7; author reply 4647.PubMedCrossRefGoogle Scholar
  150. 150.
    Heider U, Langelotz C, Jakob C, et al. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 2003; 9:1436–40.PubMedGoogle Scholar
  151. 151.
    Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A 2001; 98:11581–6.PubMedCrossRefGoogle Scholar
  152. 152.
    Okada T, Akikusa S, Okuno H, Kodaka M. Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. Clin Exp Metastasis 2003; 20:639–46.PubMedCrossRefGoogle Scholar
  153. 153.
    Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001; 98:3527–33.PubMedCrossRefGoogle Scholar
  154. 154.
    Seidel C, HjertnerO, Abildgaard N, et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001; 98:2269–71.PubMedCrossRefGoogle Scholar
  155. 155.
    Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001; 98:3534–40.PubMedCrossRefGoogle Scholar
  156. 156.
    Vanderkerken K, De Leenheer E, Shipman C, et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003; 63:287–9.PubMedGoogle Scholar
  157. 157.
    Croucher PI, Shipman CM, Van Camp B, Vanderkerken K. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. Cancer 2003; 97:818–24.PubMedCrossRefGoogle Scholar
  158. 158.
    Croucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 2003; 18:482–92.PubMedCrossRefGoogle Scholar
  159. 159.
    Sezer O. Myeloma bone disease. Hematology 2005; 10(Suppl 1):19–24.PubMedCrossRefGoogle Scholar
  160. 160.
    Heath DJ, Vanderkerken K, Cheng X, et al. An osteoprotegerin-like pepti-domimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma. Cancer Res2007; 67:202–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Faustino Mollinedo
    • 1
  1. 1.Centro de Investigacion del Cancer Instituto de Biologia Molecular y Celular del CancerConsejo Superior de Investigaciones Cientifi cas-Universidad de SalamancaSpain

Personalised recommendations